Leegwater, Emiel Strik, Anne Wilms, Erik B Bosma, Liesbeth B E Burger, David M Ottens, Thomas H van Nieuwkoop, Cees
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
We report a case of a man with COVID-19 who developed acute hepatotoxicity related to remdesivir with probable interaction of P-glycoprotein (P-gp) inhibitors. Until further details on this interaction become available, we recommend physicians to be cautious with the prescription of P-gp inhibitors in patients receiving remdesivir therapy. © The Au...
Sultan, Sherif Acharya, Yogesh
Published in
Vascular
The world is witnessing an unprecedented crisis with Coronavirus disease 2019 (COVID-19). It is important to accurately analyze the available evidence to provide correct clinical guidance for optimal patient care. We aim to discuss current clinical evidence regarding chloroquine, hydroxychloroquine, azithromycin, remdesivir, and the cardiovascular ...
Khan, Salman Ali Zia, Komal Ashraf, Sajda Uddin, Reaz Ul-Haq, Zaheer
Published in
Journal of biomolecular structure & dynamics
Recently, the world has witnessed outbreak of a novel Coronavirus (SARS-CoV-2), the virus which initially emerged in Wuhan, China has now made its way to a large part of the world, resulting in a public emergency of international concern. The functional importance of Chymotrypsin-like protease (3CLpro) in viral replication and maturation turns it i...
Nguyen, Ryan Goodell, Jennifer Shankarappa, Priya S. Zimmerman, Sara Yin, Tyler Peer, Cody J. Figg, William D.
Published in
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
Remdesivir, formerly GS-5734, has recently become the first antiviral drug approved by the U.S. Food and Drug Administration (FDA) to treat COVID-19, the disease caused by SARS-CoV-2. Therapeutic dosing and pharmacokinetic studies require a simple, sensitive, and selective validated assay to quantify drug concentrations in clinical samples. Therefo...
Mehta, Ravindra M. Bansal, Sameer Bysani, Suhitha Kalpakam, Hariprasad
Published in
International Journal of Infectious Diseases
Objectives Remdesivir is the current recommended anti-viral treatment in moderate-to-severe COVID-19. However, data on impact of timing of therapy, efficacy, and safety are limited. We evaluated the impact of timing of remdesivir initiation (symptom-onset to remdesivir treatment [SORT] interval) on in-hospital all-cause mortality in patients with m...
Gutierrez, María Del Mar Mur, Isabel Mateo, María Gracia Vidal, Francesc Domingo, Pere
Published in
Expert Opinion on Pharmacotherapy
Introduction When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed. Areas covered Data from observational studies suggest similar incidence attacks of SARS-CoV-2 infection in people living with HIV (PLWH) and HIV-uninfected popula...
Ye, Zi-Wei Yuan, Shuofeng Chan, Jasper Fuk-Woo Zhang, Anna Jinxia Yu, Ching-Yun Ong, Chon Phin Yang, Dong Chan, Chris Chun-Yiu Tang, Kaiming Cao, Jianli
...
Published in
Emerging Microbes & Infections
Effective treatments for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Dexamethasone has been shown to confer survival benefits to certain groups of hospitalized patients, but whether glucocorticoids such as dexamethasone and methylprednisolone should be used together...
Fox, Erin R Shah, Mark Vinik, Russell Brown, Sam Buckel, Whitney Webb, Brandon Zarndt, Janet Evans, Megan Mesdaghi, Pejman Imlay, Hannah N
...
Published in
American Journal of Health-System Pharmacy: AJHP
Purpose This report describes our process of 4 health systems coming together to agree on standard use criteria for remdesivir as a coronavirus disease 2019 (COVID-19) treatment for patients in Utah. We hope our process provides a framework for remdesivir use in other states and insights on future use of other therapeutic agents that may also be in...
ÇUBUK, Hasan ÖZBİL, Mehmet
Published in
Turkish Journal of Chemistry
The new type of coronavirus, SARS-CoV-2 has affected more than 22.6 million people worldwide. Since the first day the virus was spotted in Wuhan, China, numerous drug design studies have been conducted all over the globe. Most of these studies target the receptor-binding domain of spike protein of SARS-CoV-2, which is known to bind to the human ACE...
Agarwala, Anandita Liu, Jing Ballantyne, Christie M. Virani, Salim S.
Published in
Current Cardiovascular Risk Reports
Purpose of ReviewIn 2018, the AHA/ACC Multi-Society Cholesterol Guidelines introduced the novel concept of risk-enhancing factors to be used as a supplement to the pooled cohort risk equations to personalize atherosclerotic cardiovascular disease risk assessment in primary prevention. In this review, we discuss the rationale and evidence behind eac...
